Are you over 18 and want to see adult content?
More Annotations
A complete backup of bertelsmann-stiftung.de
Are you over 18 and want to see adult content?
A complete backup of whosephonenumberisthisnow.com
Are you over 18 and want to see adult content?
A complete backup of davincismuse.com
Are you over 18 and want to see adult content?
A complete backup of localmotionhawaii.com
Are you over 18 and want to see adult content?
A complete backup of solucanbilgini.com
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of plastykstudios.com.au
Are you over 18 and want to see adult content?
A complete backup of molitor-berlin.de
Are you over 18 and want to see adult content?
A complete backup of paleomomnoms.com
Are you over 18 and want to see adult content?
A complete backup of chelseanews24.com
Are you over 18 and want to see adult content?
A complete backup of autografia.com.br
Are you over 18 and want to see adult content?
A complete backup of cole-upskirt.net
Are you over 18 and want to see adult content?
Text
around the world.
MAJ. GENERAL (RET.) ELDER GRANGER, M.D. Major General Granger, M.D., serves as the Chief Medical Officer. He is currently the President and CEO of The 5Ps, LLC, a Centennial, Colo.-based health-care, education, and leadership consulting organization, since August 6, 2009. Prior to his retirement from the US Army on July 1, 2009, MG Granger served as the Deputy Director andProgram
CARL BERG | BOARD OF DIRECTORS | ABOUT | BERG Carl is one of the co-visionaries of Silicon Valley where he has been developing, leasing, owning and operated R&D and office buildings since 1963. Carl has built or owned over 15 million square feet of commercial real estate., Mr. Berg was the Chairman of the Board and CEO of Mission West Properties, Inc., from 1997 until its sale in2012.
MITCH GRAY | FOUNDERS | ABOUT | BERG Mitch Gray. Mitch Gray is a Co-Founder of BERG, a Boston-based biopharma company housing fully integrated discovery, clinical, analytics, and diagnostics divisions. He also serves as Founder, President, and Chief Executive Officer of the Nashville-based Pathfinder Management, a company that offers key incubation managementand operations
NIVEN R. NARAIN, PH.D. Niven R. Narain, Ph.D. Dr. Niven R. Narain is Co-Founder, President & CEO of Berg, a Boston-based biopharma driving next generation drug and diagnostic development by combining patient-driven biology and Bayesian AI. He is a pioneer in technology development at the intersection of Biology and AI and is inventor of the InterrogativeBiology
NIVEN R. NARAIN, PH.D. Co-Founder, President & Chief Executive Officer. Dr. Niven R. Narain is Co-Founder, President & CEO of Berg, a Boston-based biopharma driving next generation drug and diagnostic development by combining patient-driven biology and Bayesian AI. He is a pioneer in technology development at the intersection of Biology and AI and is inventor ofthe
MICHAEL KIEBISH
Michael Kiebish, Ph.D., is the Chief Precision Medicine Officer. Dr. Kiebish joined BERG in 2012 and has overseen numerous technical and translational roles during his tenure. Dr. Kiebish and his team have pioneered novel systems medicine strategies for biomarker, pharmaceutical and theranostic development to ensure targetpopulations’ are
STEPHANE GESTA PH.D. Stephane Gesta, Ph.D. is Senior Vice President of Research & Development and Science Strategy at BERG. Dr. Gesta joined BERG in 2011 and drives the company’s preclinical programs into IND filing and first in human studies. His vision for healthcare is to bring the right medication to the right patient. He focuses on translatingBERG’s
VIVEK K. VISHNUDAS, PH.D. In his role as Senior Vice President, Drug Discovery & Platform Sciences, Vivek Vishnudas, Ph.D., oversees the development of experimental therapeutics from conception and drug discovery to first-in-human studies. Drug-discovery programs are based on the novel disease targets identified through the use of Interrogative Biology.
DAVID BUTZE
David Butze serves as a board director to BERG. David is a former CEO and President of several Services Organizations. His experience includes C suite positions at public companies, leading an independent professional services firm and serving as president of the US unit of BERG | BACK TO BIOLOGY FOR A HEALTHIER TOMORROWABOUT USRESEARCH & DEVELOPMENTPARTNERSMEDIACAREERSCONTACT BERG is a clinical-stage, AI-powered biotechnology company taking a bold ‘Back to Biology ™’ approach to healthcare. By leveraging our proprietary intelligence platform – Interrogative Biology ®, our goal is to map disease and revolutionize treatments for patientsaround the world.
MAJ. GENERAL (RET.) ELDER GRANGER, M.D. Major General Granger, M.D., serves as the Chief Medical Officer. He is currently the President and CEO of The 5Ps, LLC, a Centennial, Colo.-based health-care, education, and leadership consulting organization, since August 6, 2009. Prior to his retirement from the US Army on July 1, 2009, MG Granger served as the Deputy Director andProgram
CARL BERG | BOARD OF DIRECTORS | ABOUT | BERG Carl is one of the co-visionaries of Silicon Valley where he has been developing, leasing, owning and operated R&D and office buildings since 1963. Carl has built or owned over 15 million square feet of commercial real estate., Mr. Berg was the Chairman of the Board and CEO of Mission West Properties, Inc., from 1997 until its sale in2012.
MITCH GRAY | FOUNDERS | ABOUT | BERG Mitch Gray. Mitch Gray is a Co-Founder of BERG, a Boston-based biopharma company housing fully integrated discovery, clinical, analytics, and diagnostics divisions. He also serves as Founder, President, and Chief Executive Officer of the Nashville-based Pathfinder Management, a company that offers key incubation managementand operations
NIVEN R. NARAIN, PH.D. Niven R. Narain, Ph.D. Dr. Niven R. Narain is Co-Founder, President & CEO of Berg, a Boston-based biopharma driving next generation drug and diagnostic development by combining patient-driven biology and Bayesian AI. He is a pioneer in technology development at the intersection of Biology and AI and is inventor of the InterrogativeBiology
NIVEN R. NARAIN, PH.D. Co-Founder, President & Chief Executive Officer. Dr. Niven R. Narain is Co-Founder, President & CEO of Berg, a Boston-based biopharma driving next generation drug and diagnostic development by combining patient-driven biology and Bayesian AI. He is a pioneer in technology development at the intersection of Biology and AI and is inventor ofthe
MICHAEL KIEBISH
Michael Kiebish, Ph.D., is the Chief Precision Medicine Officer. Dr. Kiebish joined BERG in 2012 and has overseen numerous technical and translational roles during his tenure. Dr. Kiebish and his team have pioneered novel systems medicine strategies for biomarker, pharmaceutical and theranostic development to ensure targetpopulations’ are
STEPHANE GESTA PH.D. Stephane Gesta, Ph.D. is Senior Vice President of Research & Development and Science Strategy at BERG. Dr. Gesta joined BERG in 2011 and drives the company’s preclinical programs into IND filing and first in human studies. His vision for healthcare is to bring the right medication to the right patient. He focuses on translatingBERG’s
VIVEK K. VISHNUDAS, PH.D. In his role as Senior Vice President, Drug Discovery & Platform Sciences, Vivek Vishnudas, Ph.D., oversees the development of experimental therapeutics from conception and drug discovery to first-in-human studies. Drug-discovery programs are based on the novel disease targets identified through the use of Interrogative Biology.
DAVID BUTZE
David Butze serves as a board director to BERG. David is a former CEO and President of several Services Organizations. His experience includes C suite positions at public companies, leading an independent professional services firm and serving as president of the US unit of BERG | BACK TO BIOLOGY FOR A HEALTHIER TOMORROW BERG is a clinical-stage, AI-powered biotechnology company taking a bold ‘Back to Biology ™’ approach to healthcare. By leveraging our proprietary intelligence platform – Interrogative Biology ®, our goal is to map disease and revolutionize treatments for patientsaround the world.
RESEARCH & DEVELOPMENT Research and Development. BERG is a clinical-stage, AI-powered biotechnology company taking a bold ‘Back to Biology™, approach to healthcare. By leveraging our proprietary intelligence platform – Interrogative Biology®, our goal is to map disease and revolutionize treatments for patients around the world. Choose from the optionsbelow to
CONTACT | BERG
BERG is making headlines. Click here to see the latest breaking news, interviews, and press releases.Click here to see the latest breaking news, interviews, and press releases. BERG FUELS STUDY OF AFRICAN-AMERICAN COVID-19 PATIENTS February 15, 2020. The December 2019 issue of Nature magazine describes the unique potential of the BERG platform in combining patient biology & artificial intelligence for drug and clinical development, highlights its use in the development of BPM 31510 inoncology.
PARTNERS | BERG
Our partnersand investors. Our partners. and investors. BERG understands that strong collaborations are key to driving progress. We have fostered many relationships with partners who share our goals of bringing innovative healthcare solutions to patients and healthcareprofessionals.
NIVEN R. NARAIN, PH.D. Niven R. Narain, Ph.D. Dr. Niven R. Narain is Co-Founder, President & CEO of Berg, a Boston-based biopharma driving next generation drug and diagnostic development by combining patient-driven biology and Bayesian AI. He is a pioneer in technology development at the intersection of Biology and AI and is inventor of the InterrogativeBiology
BERG LEADERSHIP TEAM VIVEK K. VISHNUDAS, Ph.D. Senior Vice President, Drug Discovery & Platform Sciences About Us. Leadership Team; Founders; Board ofDirectors
ELDER GRANGER
Director. Major General Granger, M.D., serves as a board director for BERG. He is currently the President and CEO of The 5Ps, LLC, a Centennial, Colo.-based health-care, education, and leadership consulting organization, since August 6, 2009. Prior to his retirement from the US Army on July 1, 2009, MG Granger served as the DeputyDirector and
STEPHANE GESTA PH.D. Stephane Gesta, Ph.D. is Senior Vice President of Research & Development and Science Strategy at BERG. Dr. Gesta joined BERG in 2011 and drives the company’s preclinical programs into IND filing and first in human studies. His vision for healthcare is to bring the right medication to the right patient. He focuses on translatingBERG’s
CHAS BOUNTRA, PH.D.
Chas Bountra, Ph.D., is the Pro-Vice Chancellor for Innovation and Professor of Translational Medicine and Chief Scientist of Structural Genomics Consortium Oxford, Nuffield Department of Medicine, University of Oxford. He is also a Visiting Professor in Neuroscience and Mental Health at BERG | BACK TO BIOLOGY FOR A HEALTHIER TOMORROWABOUT USRESEARCH & DEVELOPMENTPARTNERSMEDIACAREERSCONTACT BERG is a clinical-stage, AI-powered biotechnology company taking a bold ‘Back to Biology ™’ approach to healthcare. By leveraging our proprietary intelligence platform – Interrogative Biology ®, our goal is to map disease and revolutionize treatments for patientsaround the world.
MAJ. GENERAL (RET.) ELDER GRANGER, M.D. Major General Granger, M.D., serves as the Chief Medical Officer. He is currently the President and CEO of The 5Ps, LLC, a Centennial, Colo.-based health-care, education, and leadership consulting organization, since August 6, 2009. Prior to his retirement from the US Army on July 1, 2009, MG Granger served as the Deputy Director andProgram
CARL BERG | BOARD OF DIRECTORS | ABOUT | BERG Carl is one of the co-visionaries of Silicon Valley where he has been developing, leasing, owning and operated R&D and office buildings since 1963. Carl has built or owned over 15 million square feet of commercial real estate., Mr. Berg was the Chairman of the Board and CEO of Mission West Properties, Inc., from 1997 until its sale in2012.
MITCH GRAY | FOUNDERS | ABOUT | BERG Mitch Gray. Mitch Gray is a Co-Founder of BERG, a Boston-based biopharma company housing fully integrated discovery, clinical, analytics, and diagnostics divisions. He also serves as Founder, President, and Chief Executive Officer of the Nashville-based Pathfinder Management, a company that offers key incubation managementand operations
NIVEN R. NARAIN, PH.D. Niven R. Narain, Ph.D. Dr. Niven R. Narain is Co-Founder, President & CEO of Berg, a Boston-based biopharma driving next generation drug and diagnostic development by combining patient-driven biology and Bayesian AI. He is a pioneer in technology development at the intersection of Biology and AI and is inventor of the InterrogativeBiology
NIVEN R. NARAIN, PH.D. Co-Founder, President & Chief Executive Officer. Dr. Niven R. Narain is Co-Founder, President & CEO of Berg, a Boston-based biopharma driving next generation drug and diagnostic development by combining patient-driven biology and Bayesian AI. He is a pioneer in technology development at the intersection of Biology and AI and is inventor ofthe
MICHAEL KIEBISH
Michael Kiebish, Ph.D., is the Chief Precision Medicine Officer. Dr. Kiebish joined BERG in 2012 and has overseen numerous technical and translational roles during his tenure. Dr. Kiebish and his team have pioneered novel systems medicine strategies for biomarker, pharmaceutical and theranostic development to ensure targetpopulations’ are
STEPHANE GESTA PH.D. Stephane Gesta, Ph.D. is Senior Vice President of Research & Development and Science Strategy at BERG. Dr. Gesta joined BERG in 2011 and drives the company’s preclinical programs into IND filing and first in human studies. His vision for healthcare is to bring the right medication to the right patient. He focuses on translatingBERG’s
VIVEK K. VISHNUDAS, PH.D. In his role as Senior Vice President, Drug Discovery & Platform Sciences, Vivek Vishnudas, Ph.D., oversees the development of experimental therapeutics from conception and drug discovery to first-in-human studies. Drug-discovery programs are based on the novel disease targets identified through the use of Interrogative Biology.
DAVID BUTZE
David Butze serves as a board director to BERG. David is a former CEO and President of several Services Organizations. His experience includes C suite positions at public companies, leading an independent professional services firm and serving as president of the US unit of BERG | BACK TO BIOLOGY FOR A HEALTHIER TOMORROWABOUT USRESEARCH & DEVELOPMENTPARTNERSMEDIACAREERSCONTACT BERG is a clinical-stage, AI-powered biotechnology company taking a bold ‘Back to Biology ™’ approach to healthcare. By leveraging our proprietary intelligence platform – Interrogative Biology ®, our goal is to map disease and revolutionize treatments for patientsaround the world.
MAJ. GENERAL (RET.) ELDER GRANGER, M.D. Major General Granger, M.D., serves as the Chief Medical Officer. He is currently the President and CEO of The 5Ps, LLC, a Centennial, Colo.-based health-care, education, and leadership consulting organization, since August 6, 2009. Prior to his retirement from the US Army on July 1, 2009, MG Granger served as the Deputy Director andProgram
CARL BERG | BOARD OF DIRECTORS | ABOUT | BERG Carl is one of the co-visionaries of Silicon Valley where he has been developing, leasing, owning and operated R&D and office buildings since 1963. Carl has built or owned over 15 million square feet of commercial real estate., Mr. Berg was the Chairman of the Board and CEO of Mission West Properties, Inc., from 1997 until its sale in2012.
MITCH GRAY | FOUNDERS | ABOUT | BERG Mitch Gray. Mitch Gray is a Co-Founder of BERG, a Boston-based biopharma company housing fully integrated discovery, clinical, analytics, and diagnostics divisions. He also serves as Founder, President, and Chief Executive Officer of the Nashville-based Pathfinder Management, a company that offers key incubation managementand operations
NIVEN R. NARAIN, PH.D. Niven R. Narain, Ph.D. Dr. Niven R. Narain is Co-Founder, President & CEO of Berg, a Boston-based biopharma driving next generation drug and diagnostic development by combining patient-driven biology and Bayesian AI. He is a pioneer in technology development at the intersection of Biology and AI and is inventor of the InterrogativeBiology
NIVEN R. NARAIN, PH.D. Co-Founder, President & Chief Executive Officer. Dr. Niven R. Narain is Co-Founder, President & CEO of Berg, a Boston-based biopharma driving next generation drug and diagnostic development by combining patient-driven biology and Bayesian AI. He is a pioneer in technology development at the intersection of Biology and AI and is inventor ofthe
MICHAEL KIEBISH
Michael Kiebish, Ph.D., is the Chief Precision Medicine Officer. Dr. Kiebish joined BERG in 2012 and has overseen numerous technical and translational roles during his tenure. Dr. Kiebish and his team have pioneered novel systems medicine strategies for biomarker, pharmaceutical and theranostic development to ensure targetpopulations’ are
STEPHANE GESTA PH.D. Stephane Gesta, Ph.D. is Senior Vice President of Research & Development and Science Strategy at BERG. Dr. Gesta joined BERG in 2011 and drives the company’s preclinical programs into IND filing and first in human studies. His vision for healthcare is to bring the right medication to the right patient. He focuses on translatingBERG’s
VIVEK K. VISHNUDAS, PH.D. In his role as Senior Vice President, Drug Discovery & Platform Sciences, Vivek Vishnudas, Ph.D., oversees the development of experimental therapeutics from conception and drug discovery to first-in-human studies. Drug-discovery programs are based on the novel disease targets identified through the use of Interrogative Biology.
DAVID BUTZE
David Butze serves as a board director to BERG. David is a former CEO and President of several Services Organizations. His experience includes C suite positions at public companies, leading an independent professional services firm and serving as president of the US unit of BERG | BACK TO BIOLOGY FOR A HEALTHIER TOMORROW BERG is a clinical-stage, AI-powered biotechnology company taking a bold ‘Back to Biology ™’ approach to healthcare. By leveraging our proprietary intelligence platform – Interrogative Biology ®, our goal is to map disease and revolutionize treatments for patientsaround the world.
RESEARCH & DEVELOPMENT Research and Development. BERG is a clinical-stage, AI-powered biotechnology company taking a bold ‘Back to Biology™, approach to healthcare. By leveraging our proprietary intelligence platform – Interrogative Biology®, our goal is to map disease and revolutionize treatments for patients around the world. Choose from the optionsbelow to
CONTACT | BERG
BERG is making headlines. Click here to see the latest breaking news, interviews, and press releases.Click here to see the latest breaking news, interviews, and press releases. BERG FORMS RESEARCH COLLABORATION WITH BOEHRINGER FRAMINGHAM, Mass., May 6, 2020 /PRNewswire/ — BERG, a clinical-stage biotech company that uses artificial intelligence (AI) to research diseases and develop innovative treatments, today announced a new collaboration with Boehringer Ingelheim around understanding the multifaceted nature of the spectrum of inflammatory diseases and seeks to unravel the associated biological drivers. BERG FUELS STUDY OF AFRICAN-AMERICAN COVID-19 PATIENTS February 15, 2020. The December 2019 issue of Nature magazine describes the unique potential of the BERG platform in combining patient biology & artificial intelligence for drug and clinical development, highlights its use in the development of BPM 31510 inoncology.
BERG PRESENTS RESULTS OF PHASE 1 CLINICAL STUDY IN FRAMINGHAM, Mass., June 1, 2020 /PRNewswire/ — BERG, a clinical-stage biotech company that uses Artificial Intelligence (AI) to research diseases and develop innovative treatments, today announced results from a Phase 1 clinical study of its investigational drug, BPM 31510 (novel ubidecarenone formulation) in glioblastoma (GBM). The study, presented at the 2020 American Society of Clinical BERG LEADERSHIP TEAM VIVEK K. VISHNUDAS, Ph.D. Senior Vice President, Drug Discovery & Platform Sciences About Us. Leadership Team; Founders; Board ofDirectors
ELDER GRANGER
Director. Major General Granger, M.D., serves as a board director for BERG. He is currently the President and CEO of The 5Ps, LLC, a Centennial, Colo.-based health-care, education, and leadership consulting organization, since August 6, 2009. Prior to his retirement from the US Army on July 1, 2009, MG Granger served as the DeputyDirector and
CHAS BOUNTRA, PH.D.
Chas Bountra, Ph.D., is the Pro-Vice Chancellor for Innovation and Professor of Translational Medicine and Chief Scientist of Structural Genomics Consortium Oxford, Nuffield Department of Medicine, University of Oxford. He is also a Visiting Professor in Neuroscience and Mental Health at CHEMOTHERAPY-INDUCED-ALOPECIA (CIA) BPM 31543 is a topical calcitriol formulation in clinical development for the prevention and treatment of chemotherapy-induced alopecia. The incidence of CIA within chemotherapy regimens is high: 65% of patients receiving chemotherapy develop CIA, with figures reaching as high as 80-100% with agents such as paclitaxel or doxorubicin regimens. BERG | BACK TO BIOLOGY FOR A HEALTHIER TOMORROWABOUT USRESEARCH & DEVELOPMENTPARTNERSMEDIACAREERSCONTACT BERG is a clinical-stage, AI-powered biotechnology company taking a bold ‘Back to Biology ™’ approach to healthcare. By leveraging our proprietary intelligence platform – Interrogative Biology ®, our goal is to map disease and revolutionize treatments for patientsaround the world.
BERG TO CONDUCT PHASE TWO TRIAL FOR TREATMENT OF DEADLY About BERG BERG LLC is a clinical-stage, artificial intelligence-powered biotech leveraging its proprietary platform, Interrogative Biology ®, to map disease and revolutionize treatments across oncology, neurology and rare diseases.By taking a Back to Biology ™ approach, BERG is able to identify critical biomarkers that can accelerate the discovery and development of treatments aimedat the
MEDIA KIT | MEDIA | BERG BERG is a biopharmaceutical company committed to delivering innovative healthcare solutions through a data-driven approach. BERG is the namesake of Chairman and Co-founder Carl E. Berg, who formed the company together with Co-founders Mitch Gray and Niven R. Narain in 2006. BERG utilizes AI-based machine learning to infercause-and-effect
MITCH GRAY | FOUNDERS | ABOUT | BERG Mitch Gray. Mitch Gray is a Co-Founder of BERG, a Boston-based biopharma company housing fully integrated discovery, clinical, analytics, and diagnostics divisions. He also serves as Founder, President, and Chief Executive Officer of the Nashville-based Pathfinder Management, a company that offers key incubation managementand operations
MAJ. GENERAL (RET.) ELDER GRANGER, M.D. Major General Granger, M.D., serves as the Chief Medical Officer. He is currently the President and CEO of The 5Ps, LLC, a Centennial, Colo.-based health-care, education, and leadership consulting organization, since August 6, 2009. Prior to his retirement from the US Army on July 1, 2009, MG Granger served as the Deputy Director andProgram
BERG FORMS RESEARCH COLLABORATION WITH BOEHRINGER FRAMINGHAM, Mass., May 6, 2020 /PRNewswire/ — BERG, a clinical-stage biotech company that uses artificial intelligence (AI) to research diseases and develop innovative treatments, today announced a new collaboration with Boehringer Ingelheim around understanding the multifaceted nature of the spectrum of inflammatory diseases and seeks to unravel the associated biological drivers. CARL BERG | BOARD OF DIRECTORS | ABOUT | BERGCARL BERG DUKECARL BERG MDBERG PHARMADR BERG ON THE LIVER Carl is one of the co-visionaries of Silicon Valley where he has been developing, leasing, owning and operated R&D and office buildings since 1963. Carl has built or owned over 15 million square feet of commercial real estate., Mr. Berg was the Chairman of the Board and CEO of Mission West Properties, Inc., from 1997 until its sale in2012.
PHARMACEUTICAL
Pharmaceutical Partners. BERG is partnering with AstraZeneca to identify and evaluate novel targets and therapeutics to treat neurological disorders such as Parkinson’s disease. Under this research arrangement, AstraZeneca will initially provide BERG with its curated library of central nervous system (CNS) optimized fragments toassist BERG
VIVEK K. VISHNUDAS, PH.D. In his role as Senior Vice President, Drug Discovery & Platform Sciences, Vivek Vishnudas, Ph.D., oversees the development of experimental therapeutics from conception and drug discovery to first-in-human studies. Drug-discovery programs are based on the novel disease targets identified through the use of Interrogative Biology.
MICHAEL KIEBISH
Michael Kiebish, Ph.D., is the Chief Precision Medicine Officer. Dr. Kiebish joined BERG in 2012 and has overseen numerous technical and translational roles during his tenure. Dr. Kiebish and his team have pioneered novel systems medicine strategies for biomarker, pharmaceutical and theranostic development to ensure targetpopulations’ are
BERG | BACK TO BIOLOGY FOR A HEALTHIER TOMORROWABOUT USRESEARCH & DEVELOPMENTPARTNERSMEDIACAREERSCONTACT BERG is a clinical-stage, AI-powered biotechnology company taking a bold ‘Back to Biology ™’ approach to healthcare. By leveraging our proprietary intelligence platform – Interrogative Biology ®, our goal is to map disease and revolutionize treatments for patientsaround the world.
BERG TO CONDUCT PHASE TWO TRIAL FOR TREATMENT OF DEADLY About BERG BERG LLC is a clinical-stage, artificial intelligence-powered biotech leveraging its proprietary platform, Interrogative Biology ®, to map disease and revolutionize treatments across oncology, neurology and rare diseases.By taking a Back to Biology ™ approach, BERG is able to identify critical biomarkers that can accelerate the discovery and development of treatments aimedat the
MEDIA KIT | MEDIA | BERG BERG is a biopharmaceutical company committed to delivering innovative healthcare solutions through a data-driven approach. BERG is the namesake of Chairman and Co-founder Carl E. Berg, who formed the company together with Co-founders Mitch Gray and Niven R. Narain in 2006. BERG utilizes AI-based machine learning to infercause-and-effect
MITCH GRAY | FOUNDERS | ABOUT | BERG Mitch Gray. Mitch Gray is a Co-Founder of BERG, a Boston-based biopharma company housing fully integrated discovery, clinical, analytics, and diagnostics divisions. He also serves as Founder, President, and Chief Executive Officer of the Nashville-based Pathfinder Management, a company that offers key incubation managementand operations
MAJ. GENERAL (RET.) ELDER GRANGER, M.D. Major General Granger, M.D., serves as the Chief Medical Officer. He is currently the President and CEO of The 5Ps, LLC, a Centennial, Colo.-based health-care, education, and leadership consulting organization, since August 6, 2009. Prior to his retirement from the US Army on July 1, 2009, MG Granger served as the Deputy Director andProgram
BERG FORMS RESEARCH COLLABORATION WITH BOEHRINGER FRAMINGHAM, Mass., May 6, 2020 /PRNewswire/ — BERG, a clinical-stage biotech company that uses artificial intelligence (AI) to research diseases and develop innovative treatments, today announced a new collaboration with Boehringer Ingelheim around understanding the multifaceted nature of the spectrum of inflammatory diseases and seeks to unravel the associated biological drivers. CARL BERG | BOARD OF DIRECTORS | ABOUT | BERGCARL BERG DUKECARL BERG MDBERG PHARMADR BERG ON THE LIVER Carl is one of the co-visionaries of Silicon Valley where he has been developing, leasing, owning and operated R&D and office buildings since 1963. Carl has built or owned over 15 million square feet of commercial real estate., Mr. Berg was the Chairman of the Board and CEO of Mission West Properties, Inc., from 1997 until its sale in2012.
PHARMACEUTICAL
Pharmaceutical Partners. BERG is partnering with AstraZeneca to identify and evaluate novel targets and therapeutics to treat neurological disorders such as Parkinson’s disease. Under this research arrangement, AstraZeneca will initially provide BERG with its curated library of central nervous system (CNS) optimized fragments toassist BERG
VIVEK K. VISHNUDAS, PH.D. In his role as Senior Vice President, Drug Discovery & Platform Sciences, Vivek Vishnudas, Ph.D., oversees the development of experimental therapeutics from conception and drug discovery to first-in-human studies. Drug-discovery programs are based on the novel disease targets identified through the use of Interrogative Biology.
MICHAEL KIEBISH
Michael Kiebish, Ph.D., is the Chief Precision Medicine Officer. Dr. Kiebish joined BERG in 2012 and has overseen numerous technical and translational roles during his tenure. Dr. Kiebish and his team have pioneered novel systems medicine strategies for biomarker, pharmaceutical and theranostic development to ensure targetpopulations’ are
ABOUT | BERG
BERG is a clinical-stage, artificial intelligence-powered biotech leveraging its proprietary platform, Interrogative Biology ®, to map disease and revolutionize treatments across oncology, neurology and rare diseases. By taking a Back to Biology ™ approach, BERG is able to identify critical biomarkers that can accelerate the discovery and RESEARCH & DEVELOPMENT Research and Development. BERG is a clinical-stage, AI-powered biotechnology company taking a bold ‘Back to Biology™, approach to healthcare. By leveraging our proprietary intelligence platform – Interrogative Biology®, our goal is to map disease and revolutionize treatments for patients around the world. Choose from the optionsbelow to
CONTACT | BERG
BERG is making headlines. Click here to see the latest breaking news, interviews, and press releases.Click here to see the latest breaking news, interviews, and press releases.MEDIA | BERG
BERG Presents Data Demonstrating That BPM31510 Promotes Cytotoxic T-cell Function And Influences Checkpoint Receptor Expression Patterns To Potentially Synergize Anti-Cancer Effect In Combination With I/O Therapies. Press releases. Showing 21 of 153 media posts - Page 1 of8. 1. 2.
HEALTHCARE PROFESSIONALS BERG’s Interrogative Biology is a disruptive platform for biopharma. It is based on hypothesis-free, data-driven philosophy applied to biomedical research. Interrogative Biology insight and findings are typically first-in-class molecular entities with a wide freedom to operate in a specific disease area. This platform utilizes humanCAREERS | BERG
BERG is an equal opportunity employer.. BERG LLC is an affirmative action employer and is committed to equal employment opportunity regardless of race, color, religion, gender, sex, military or veteran status, age, national origin, physical or mental disability, genetic information, marital status, sexual orientation or any other class protected by applicable federal, state or local law. BERG TO CONDUCT PHASE TWO TRIAL FOR TREATMENT OF DEADLY About BERG BERG LLC is a clinical-stage, artificial intelligence-powered biotech leveraging its proprietary platform, Interrogative Biology ®, to map disease and revolutionize treatments across oncology, neurology and rare diseases.By taking a Back to Biology ™ approach, BERG is able to identify critical biomarkers that can accelerate the discovery and development of treatments aimedat the
BERG LEADERSHIP TEAM BERG is making headlines. Click here to see the latest breaking news, interviews, and press releases.Click here to see the latest breaking news, interviews, and press releases.ELDER GRANGER
Director. Major General Granger, M.D., serves as a board director for BERG. He is currently the President and CEO of The 5Ps, LLC, a Centennial, Colo.-based health-care, education, and leadership consulting organization, since August 6, 2009. Prior to his retirement from the US Army on July 1, 2009, MG Granger served as the DeputyDirector and
BPM31510 | OUR PIPELINE | HEALTHCARE PROFESSIONALS BPM31510. BPM31510 (ubidecarenone) is BERG’s leading product candidate. BPM31510 works by correcting cancer cell metabolism, thereby reactivating apoptosis. BPM31510 is currently progressing through clinical trials for the treatment of a number of solid tumors. Early phase trials have appeared to demonstrate anti-tumor activitywith an
BERG | BACK TO BIOLOGY FOR A HEALTHIER TOMORROWABOUT USRESEARCH & DEVELOPMENTPARTNERSMEDIACAREERSCONTACT Back to Biology ™. BERG is a clinical-stage, AI-powered biotechnology company taking a bold ‘Back to Biology ™’ approach to healthcare. By leveraging our proprietary intelligence platform – Interrogative Biology ®, our goal is to map disease and revolutionizetreatments
BERG TO CONDUCT PHASE TWO TRIAL FOR TREATMENT OF DEADLY About BERG BERG LLC is a clinical-stage, artificial intelligence-powered biotech leveraging its proprietary platform, Interrogative Biology ®, to map disease and revolutionize treatments across oncology, neurology and rare diseases.By taking a Back to Biology ™ approach, BERG is able to identify critical biomarkers that can accelerate the discovery and development of treatments aimedat the
MEDIA KIT | MEDIA | BERG About BERG. BERG is a biopharmaceutical company committed to delivering innovative healthcare solutions through a data-driven approach. BERG is the namesake of Chairman and Co-founder Carl E. Berg, who formed the company together with Co-founders Mitch Gray and Niven R. Narain in 2006. MITCH GRAY | FOUNDERS | ABOUT | BERG Mitch Gray is a Co-Founder of BERG, a Boston-based biopharma company housing fully integrated discovery, clinical, analytics, and diagnostics divisions. BERG FORMS RESEARCH COLLABORATION WITH BOEHRINGER FRAMINGHAM, Mass., May 6, 2020 /PRNewswire/ — BERG, a clinical-stage biotech company that uses artificial intelligence (AI) to research diseases and develop innovative treatments, today announced a new collaboration with Boehringer Ingelheim around understanding the multifaceted nature of the spectrum of inflammatory diseases and seeks to unravel the associated biological drivers. CARL BERG | BOARD OF DIRECTORS | ABOUT | BERGCARL BERG DUKECARL BERG MDBERG PHARMADR BERG ON THE LIVER Carl E. Berg is Co-Founder, Chairman of the Board and Principal Investor of BERG. Carl is one of the co-visionaries of Silicon Valley where he has been developing, leasing, owning and operated R&D and office buildings since 1963. MAJ. GENERAL (RET.) ELDER GRANGER, M.D. Major General Granger, M.D., serves as the Chief Medical Officer. He is currently the President and CEO of The 5Ps, LLC, a Centennial, Colo.-based health-care, education, and leadership consulting organization, since August 6, 2009.PHARMACEUTICAL
BERG Analytics and Becton, Dickinson and Company are are working together to focus on the development of a medication-adherence algorithm. This will help healthcare workers identify patient populations at risk of non-compliance for improved patient supportpost-discharge.
MICHAEL KIEBISH
Michael Kiebish, Ph.D., is the Chief Precision Medicine Officer.Dr. Kiebish joined BERG in 2012 and has overseen numerous technical and translational roles during his tenure. Dr. VIVEK K. VISHNUDAS, PH.D. In his role as Senior Vice President, Drug Discovery & Platform Sciences, Vivek Vishnudas, Ph.D., oversees the development of experimental therapeutics from conception and drug discovery to BERG | BACK TO BIOLOGY FOR A HEALTHIER TOMORROWABOUT USRESEARCH & DEVELOPMENTPARTNERSMEDIACAREERSCONTACT Back to Biology ™. BERG is a clinical-stage, AI-powered biotechnology company taking a bold ‘Back to Biology ™’ approach to healthcare. By leveraging our proprietary intelligence platform – Interrogative Biology ®, our goal is to map disease and revolutionizetreatments
BERG TO CONDUCT PHASE TWO TRIAL FOR TREATMENT OF DEADLY About BERG BERG LLC is a clinical-stage, artificial intelligence-powered biotech leveraging its proprietary platform, Interrogative Biology ®, to map disease and revolutionize treatments across oncology, neurology and rare diseases.By taking a Back to Biology ™ approach, BERG is able to identify critical biomarkers that can accelerate the discovery and development of treatments aimedat the
MEDIA KIT | MEDIA | BERG About BERG. BERG is a biopharmaceutical company committed to delivering innovative healthcare solutions through a data-driven approach. BERG is the namesake of Chairman and Co-founder Carl E. Berg, who formed the company together with Co-founders Mitch Gray and Niven R. Narain in 2006. MITCH GRAY | FOUNDERS | ABOUT | BERG Mitch Gray is a Co-Founder of BERG, a Boston-based biopharma company housing fully integrated discovery, clinical, analytics, and diagnostics divisions. BERG FORMS RESEARCH COLLABORATION WITH BOEHRINGER FRAMINGHAM, Mass., May 6, 2020 /PRNewswire/ — BERG, a clinical-stage biotech company that uses artificial intelligence (AI) to research diseases and develop innovative treatments, today announced a new collaboration with Boehringer Ingelheim around understanding the multifaceted nature of the spectrum of inflammatory diseases and seeks to unravel the associated biological drivers. CARL BERG | BOARD OF DIRECTORS | ABOUT | BERGCARL BERG DUKECARL BERG MDBERG PHARMADR BERG ON THE LIVER Carl E. Berg is Co-Founder, Chairman of the Board and Principal Investor of BERG. Carl is one of the co-visionaries of Silicon Valley where he has been developing, leasing, owning and operated R&D and office buildings since 1963. MAJ. GENERAL (RET.) ELDER GRANGER, M.D. Major General Granger, M.D., serves as the Chief Medical Officer. He is currently the President and CEO of The 5Ps, LLC, a Centennial, Colo.-based health-care, education, and leadership consulting organization, since August 6, 2009.PHARMACEUTICAL
BERG Analytics and Becton, Dickinson and Company are are working together to focus on the development of a medication-adherence algorithm. This will help healthcare workers identify patient populations at risk of non-compliance for improved patient supportpost-discharge.
MICHAEL KIEBISH
Michael Kiebish, Ph.D., is the Chief Precision Medicine Officer.Dr. Kiebish joined BERG in 2012 and has overseen numerous technical and translational roles during his tenure. Dr. VIVEK K. VISHNUDAS, PH.D. In his role as Senior Vice President, Drug Discovery & Platform Sciences, Vivek Vishnudas, Ph.D., oversees the development of experimental therapeutics from conception and drug discovery toABOUT | BERG
OUR MISSION IS TO IMPROVE HUMAN HEALTH BY INTEGRATING AI AND PATIENT BIOLOGY TO DEVELOP LIFE CHANGING CARE. BERG is a clinical-stage, artificial intelligence-powered biotech leveraging its proprietary platform, Interrogative Biology ®, to map disease and revolutionize treatments across oncology, neurology and rare diseases.By taking a Back to Biology ™ approach, BERG is able to RESEARCH & DEVELOPMENT BERG is a clinical-stage, AI-powered biotechnology company taking a bold ‘Back to Biology™, approach to healthcare.By leveraging our proprietary intelligence platform – Interrogative Biology®, our goal is to map disease and revolutionize treatments for patientsaround the world.
CONTACT | BERG
BERG is making headlines. Click here to see the latest breaking news, interviews, and press releases.Click here to see the latest breaking news, interviews, and press releases.MEDIA | BERG
February 15, 2020. The December 2019 issue of Nature magazine describes the unique potential of the BERG platform in combining patient biology & artificial intelligence for drug and clinical development, highlights its use in the development of BPM 31510 inoncology.
HEALTHCARE PROFESSIONALS The BERG Interrogative Biology platform is a novel and unique approach to understanding underlying disease pathophysiology by the employment of high throughput “omics” to mine disease and normal tissue microenvironments, which are further validated by functional assays.CAREERS | BERG
BERG is an equal opportunity employer.. BERG LLC is an affirmative action employer and is committed to equal employment opportunity regardless of race, color, religion, gender, sex, military or veteran status, age, national origin, physical or mental disability, genetic information, marital status, sexual orientation or any other class protected by applicable federal, state or local law. BERG TO CONDUCT PHASE TWO TRIAL FOR TREATMENT OF DEADLY About BERG BERG LLC is a clinical-stage, artificial intelligence-powered biotech leveraging its proprietary platform, Interrogative Biology ®, to map disease and revolutionize treatments across oncology, neurology and rare diseases.By taking a Back to Biology ™ approach, BERG is able to identify critical biomarkers that can accelerate the discovery and development of treatments aimedat the
BERG LEADERSHIP TEAM BERG is making headlines. Click here to see the latest breaking news, interviews, and press releases.Click here to see the latest breaking news, interviews, and press releases.ELDER GRANGER
Major General Granger, M.D., serves as a board director for BERG. He is currently the President and CEO of The 5Ps, LLC, a Centennial, Colo.-based health-care, education, and leadership consulting organization, since August 6, 2009. BPM31510 | OUR PIPELINE | HEALTHCARE PROFESSIONALS This is a Phase II open-label, non-randomized clinical trial in patients with pancreatic cancer with trials being conducted at Beth Israel Deaconess Medical Center, Mayo Clinic, the Medical College of Wisconsin and Vita Medical Associates. Skip to main contentBerg_Logo
SITE NAVIGATION
* About Us
* Research & Development* Partners
* Media
* Careers
* Contact
Search
Search
Search
BACK TO BIOLOGY™
BERG is a clinical-stage_,_ AI-powered biotechnology company taking a bold ‘Back to Biology™’ approach to healthcare. By leveraging our proprietary intelligence platform – Interrogative Biology®, our goal is to map disease and revolutionize treatments for patientsaround the world.
OUR VISION
By harnessing the power of AI, coupled with patient biology, we aim to accelerate clinical identification and pursuit of promising therapeutic targets to treat disease. This means faster discovery and development of treatments, more effective precision treatments for individuals as well as a reduction in costs to our healthcare systems. By going ‘Back to Biology™’, we believe we can drive healthcareforward.
OUR FOCUS
ONCOLOGY
NEUROLOGY
RARE DISEASE
PROGRESS, FOR PEOPLE™ At BERG, we believe in making Progress, for People™. People not only inspire the work we do, but are at the center of our R&D. BERG harnesses the true potential of modern technology to gather trillions of data points to map diseases in unprecedented detail. This revolutionary approach aims to bring new treatments and new hope to the millions of patients and caregivers in need of novel treatmentoptions.
BERG IN THE NEWS
April 1, 2021
BERG TAPS INTO SUPERCOMPUTER TO BATTLE COVID-19 VARIANTSOctober 6, 2020
HEALTHCARE LEADERS PIONEER A NEW COLLABORATION MODEL TO TRANSFORM THE FUTURE OF DRUG DEVELOPMENTSeptember 28, 2020
BERG FUELS STUDY OF AFRICAN-AMERICAN COVID-19 PATIENTSJune 18, 2020
ENERGY DEPARTMENT USES SUPERCOMPUTERS TO TACKLE COVID-19May 6, 2020
BOEHRINGER INGELHEIM ADDS SECOND AI PARTNER IN A MONTHMarch 5, 2020
TRANSFORMING DRUG DISCOVERY THROUGH ARTIFICIAL INTELLIGENCE.February 15, 2020
THE DECEMBER 2019 ISSUE OF NATURE MAGAZINE DESCRIBES THE UNIQUE POTENTIAL OF THE BERG PLATFORM IN COMBINING PATIENT BIOLOGY & ARTIFICIAL INTELLIGENCE FOR DRUG AND CLINICAL DEVELOPMENT, HIGHLIGHTS ITS USE IN THE DEVELOPMENT OF BPM 31510 IN ONCOLOGY.February 14, 2020
POD OF ASCLEPIUS PODCAST: BERG CEO ON VALUE-DRIVEN DATA & AI FORPHARMA INNOVATION
February 14, 2020
A.I. CANCER DRUGMAKER MEETING WITH BIG PHARMA COMPANIESView all news
Berg_Logo
* About Us
* Leadership Team
* Founders
* Board of Directors * Scientific Advisory Board * Research & Development * Healthcare Professionals* Our Pipeline
* Publications
* Patients and Caregivers* Our Science
* Epidermolysis Bullosa (EB) * Chemotherapy-Induced-Alopecia (CIA)* Pancreatic Cancer
* Expanded Access and Compassionate Use* Medical Resources
* Clinical Trials
* Partners
* Pharmaceutical
* Healthcare
* Academic
* Government
* Media
* News Features
* Press Releases
* Events
* Media Kit
* Clinical Trials
* Careers
* Join Our Team
* Contact
* Investor contact
* Media contact
* Partner contact
* Connect with us
Headquarters and Innovation Center 500 Old Connecticut Path Framingham, MA 01701Tel: (617) 588-0083
Email: Info@Berghealth.com* © 2021 BERG LLC
* Legal
* Visit BERG on LinkedIn * Visit BERG on Twitter * Visit BERG on Facebook * Visit the BERG YouTube channelBERG IN THE NEWS!
BERG IS MAKING HEADLINES. CLICK HERE TO SEE THE LATEST BREAKING NEWS, INTERVIEWS, AND PRESS RELEASES.__
Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0